Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
LetterLetter

Just Another Case of Sjögren’s Syndrome?

LEROY R. LARD and THOMAS W.J. HUIZINGA
The Journal of Rheumatology June 2010, 37 (6) 1363; DOI: https://doi.org/10.3899/jrheum.100027
LEROY R. LARD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: l.r.lard@lumc.nl
THOMAS W.J. HUIZINGA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

A 60-year-old woman was seen at the outpatient clinic of the Department of Rheumatology because of increased complaints of xerophthalmia. In 1997, she had already been diagnosed with Sjögren’s syndrome (SS) based on xerophthalmia, xerostomia, bilateral salivary gland swelling, and positive sialography showing chronic inflammation without local obstruction. Antinuclear antibodies (ANA) and anti-SSA/SSB were negative. Because of persistent progressive salivary gland swelling at that time, a total bilateral submandibular gland excision was performed as development of non-Hodgkin lymphoma as a complication of SS was suspected. Histology showed sialoadenitis as seen in SS without signs of lymphoma. In 2002, a renal biopsy performed because of increased creatinine level without proteinuria revealed focal global glomerulosclerosis with interstitial nephritis due to SS or chronic ischemia. In an attempt to treat possible active interstitial nephritis due to SS, she was treated with 30 mg of prednisone and azathioprine. Prednisone was stopped after 6 months and azathioprine after one year, however, there was no effect on renal function.

A current physical examination revealed no serious abnormalities. Blood pressure was 150/90 mmHg. There were no signs of arthritis. The Schirmer test (without eye drops) revealed normal results with 15 mm and 12 mm wetting on the right and left side, respectively, after 5 minutes.

Laboratory tests showed a normal complete blood count, erythrocyte sedimentation rate (ESR) of 39 mm/h, C-reactive protein level of 7 mg/l, and stable creatinine level of 158 μmol/l. Rheumatoid factor, ANA, and anti-SSA/SSB were negative. The protein spectrum showing an elevated gamma fraction of 24.8 g/l. Immunoelectropheresis revealed an elevated total IgG of 29 g/l (normal range < 16 g/l). Further analysis of the IgG showed mainly enhanced level of IgG4 of 19.9 g/l (normal range < 1.4 g/l). Unfortunately, we were not able to perform IgG4 staining on the former tissue samples of the salivary gland and kidney because of technical issues.

At this point, we considered that the patient did not have SS but most probably Mikulicz’s disease (MD)/IgG4-positive multiorgan lymphoproliferative syndrome (IgG4+ MOLPS) based on the exceptionally elevated IgG4 levels1. As this patient only had mild complaints of xerophthalmia with no major organ involvement at this time, no immunosuppressive therapy was indicated.

MD is a disease that involves bilateral enlargement of the salivary and lacrimal glands associated with prominent mononuclear infiltration. Since patients with MD often have complaints of xerophthalmia, xerostomia, and bilateral salivary gland swelling, but no SSA/SSB autoantibodies, this disease has been characterized in the past as a seronegative subtype of primary SS. It has been reported that MD patients frequently have increased serum IgG4 concentrations and abundant infiltration of IgG4-positive plasma cells in the salivary and lacrimal glands2. The ratio of serum IgG4 to total IgG is 34.85%, while in healthy controls the ratio is about 4%3. In SS patients serum IgG4 is not elevated and no infiltration of IgG4-positive plasmacytes is observed4. High serum IgG4 concentrations have also been found in a small number of pathological conditions, such as autoimmune pancreatitis, atopic dermatitis, pemphigus vulgaris, and even interstitial nephritis1,5,6. Therefore, recent reports proposed a new clinical entity called the IgG4+ MOLPS for the above mentioned diseases including MD7.

The histopathological characteristics are similar showing degeneration and disappearance of normal tissue by severe mononuclear infiltration, proliferation of ductal epithelial cells and duct stenosis, formation of myoepithelial islands, and cystic dilatation of peripheral ducts8. A high frequency of apoptosis has been seen in SS, however, Tsubota, et al9,10 reported that the frequency of apoptosis in gland cells is significantly decreased in IgG4+ MOLPS. Moreover, it has been reported that sialography in patients with IgG4+ MOLPS did not show a punctuate sialectasis. This seems to indicate a lack of glandular destruction in IgG4+ MOLPS. This could explain why salivary function can improve significantly in IgG4+ MOLPS after steroid therapy, whereas SS is considered unable to improve using corticosteroids due to irreversible damage of the glands3. These findings strongly suggest that IgG4+ MOLPS represents both a clinical and histopathological separate entity from SS.

Our patient was eventually diagnosed as having IgG4+ MOLPS. In retrospect, an adequate treatment with corticosteroids in the past might have spared her from a bilateral submandibular gland excision. In 2002, the nephrologist treated her with prednisone (30 mg daily) for suspected interstitial nephritis without improvement. Interstitial nephritis has also been described in the IgG4-related diseases. However, the lack of response on prednisone at that time might suggest either a late chronic stage of renal disease or insufficient immunosuppressive treatment since other case studies described successful treatment of interstitial nephritis with high dose methylprednisolone pulse therapy followed by 60 mg/day prednisone5,6.

IgG4+ MOLPS should be considered in patients with sicca complaints and negative SSA/SSB antibodies.

REFERENCES

  1. 1.↵
    1. Tabata T,
    2. Kamisawa T,
    3. Takuma K,
    4. Anjiki H,
    5. Egawa N,
    6. Kurata M,
    7. et al.
    Serum IgG4 concentrations and IgG4-related sclerosing disease. Clin Chim Acta 2009;408:25–8.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Yamamoto M,
    2. Harada S,
    3. Ohara M,
    4. Suzuki C,
    5. Naishiro Y,
    6. Yamamoto H,
    7. et al.
    Clinical and pathological differences between Mikulicz’s disease and Sjogren’s syndrome. Rheumatology (Oxford) 2005;44:227–34.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Yamamoto M,
    2. Harada S,
    3. Ohara M,
    4. Suzuki C,
    5. Naishiro Y,
    6. Yamamoto H,
    7. et al.
    Beneficial effects of steroid therapy for Mikulicz’s disease. Rheumatology (Oxford) 2005;44:1322–3.
    OpenUrlFREE Full Text
  4. 4.↵
    1. Yamamoto M,
    2. Takahashi H,
    3. Ohara M,
    4. Suzuki C,
    5. Naishiro Y,
    6. Yamamoto H,
    7. et al.
    A new conceptualization for Mikulicz’s disease as an IgG4-related plasmacytic disease. Mod Rheumatol 2006;16:335–40.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Shimoyama K,
    2. Ogawa N,
    3. Sawaki T,
    4. Karasawa H,
    5. Masaki Y,
    6. Kawabata H,
    7. et al.
    A case of Mikulicz’s disease complicated with interstitial nephritis successfully treated by high-dose corticosteroid. Mod Rheumatol 2006;16:176–82.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Aoki A,
    2. Sato K,
    3. Itabashi M,
    4. Takei T,
    5. Yoshida T,
    6. Arai J,
    7. et al.
    A case of Mikulicz’s disease complicated with severe interstitial nephritis associated with IgG4. Clin Exp Nephrol 2009;13:367–72.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Masaki Y,
    2. Dong L,
    3. Kurose N,
    4. Kitagawa K,
    5. Morikawa Y,
    6. Yamamoto M,
    7. et al.
    Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis 2009;68:1310–5.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Morgan WS,
    2. Castleman B
    . A clinicopathologic study of Mikulicz’s disease. Am J Pathol 1953;29:471–503.
    OpenUrlPubMed
  9. 9.↵
    1. Tsubota K,
    2. Fujita H,
    3. Tsuzaka K,
    4. Takeuchi T
    . Mikulicz’s disease and Sjogren’s syndrome. Invest Ophthalmol Vis Sci 2000;41:1666–73.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Tsubota K,
    2. Fujita H,
    3. Tadano K,
    4. Onoda N,
    5. Tsuzaka K,
    6. Takeuchi T
    . Abnormal expression and function of Fas ligand of lacrimal glands and peripheral blood in Sjogren’s syndrome patients with enlarged exocrine glands. Clin Exp Immunol 2002;129:177–82.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 37, Issue 6
1 Jun 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Just Another Case of Sjögren’s Syndrome?
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Just Another Case of Sjögren’s Syndrome?
LEROY R. LARD, THOMAS W.J. HUIZINGA
The Journal of Rheumatology Jun 2010, 37 (6) 1363; DOI: 10.3899/jrheum.100027

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Just Another Case of Sjögren’s Syndrome?
LEROY R. LARD, THOMAS W.J. HUIZINGA
The Journal of Rheumatology Jun 2010, 37 (6) 1363; DOI: 10.3899/jrheum.100027
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
    • REFERENCES
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • What It Means to Me to Have Juvenile Arthritis: One Patient’s Definition
  • COVID-19 in Patients With Connective Tissue Disease-related Interstitial Lung Disease
  • Clinical and Radiological Remission of Osteoarticular and Cutaneous Lesions in SAPHO Patients Treated With Secukinumab: A Case Series
Show more Letters

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire